KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Study summary

Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedSelinexor

The study team can explain what participation involves.

Who it may be forCarcinoma, Neuroendocrine

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 17, 2019 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Gabrail Cancer Center Research

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 2
Sponsor: Gabrail Cancer Center Research
Interventions being studied: Drug: Selinexor

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Written informed consent in accordance with federal, local, and institutional guidelines
Age ≥18 years
Patients must have a tissue diagnosis of any of the following:
Small cell lung cancer (SCLC) or poorly differentiated gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Poorly differentiated metastatic neuroendocrine tumors of unknown primary origin
Measurable disease: Any primary and/or metastatic mass reproducibly measurable in one or two diameters by RECIST 1.1 parameters by cat scan (CT) scan.
Objective evidence of tumor progression within 4 months prior to study entry, as defined by serial cat scan (CT) per RECIST 1.1 criteria. (At least a 20% increase in the sum of diameters of target lesions. In addition, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression).
Patients must have received at least one prior line of chemotherapy and must have exhausted any other standard-of-care treatment option.
Prior radiation and surgery is allowed. At least 3 weeks should have elapsed from surgery, chemotherapy, hepatic embolization/ chemoembolization or radioactive isotopes (i.e. Yttrium 90). In any case, disease progression must be documented after treatment.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Concomitant octreotide treatment for carcinoid syndrome is allowed for patients whose tumor has progressed while on octreotide. Patients must have been on a stable dose of octreotide two weeks prior to enrollment and must remain on a stable dose during the study.
Hematological function:
Total white blood cell count (WBC) \> 2,000/mm³
Absolute neutrophil (ANC) \> 1,000/mm³
Platelet \>100,000mm³
Adequate hepatic function within 14 days prior to C1D1: total direct bilirubin \<2 times the upper limit of normal (ULN; 1.0 mg/dL) and alanine aminotransferase (ALT) \<2.5 times ULN (30 U/L). In the case of known (radiological and/or biopsy documented) liver metastasis, ALT \<5.0 times ULN is acceptable.
Adequate renal function within 7 days prior to C1D1: estimated creatinine clearance of ≥ 30 mL/min, calculated using the formula of Cockcroft and Gault: (140-Age)
Mass (kg)/(72
creatinine mg/dL); multiply by 0.85 if female.
Blood electrolytes should be within the following normal limits: Bicarbonate (total) 18-30 mEq/L Sodium 135-147 mEq/L Potassium 3.5-5.5 mEq/L Phosphorus 1.8-2.3 mEq/L Magnesium 1.5-3.0 mEq/L Chloride 98-106 mEq/L Calcium (total) 4.5-5.5 mEq/L
Female patients of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential. Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal. For both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last dose.

Reasons someone may not be able to joinExclusion criteria

Patients who are pregnant or lactating
Patients with the following tumor types: lung carcinoid, pheochromocytomas, paragangliomas, medullary thyroid carcinomas, any other tumors with neuroendocrine features not listed in the inclusion criteria
Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤3 weeks prior to C1D1
Major surgery ≤3 weeks prior to C1D1
Unstable cardiovascular function:
Congestive heart failure (CHF) of NYHA Class ≥3 OR
Myocardial infarction (MI) within 3 months
Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose; patients with controlled infection or on prophylactic antibiotics are permitted in the study
Known to be human immunodeficiency virus (HIV) seropositive
Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus (HCV RNA) or HBsAg (HBV surface antigen)
Any underlying condition that would significantly interfere with the absorption of an oral medication
Patients who have active central nervous system (CNS) malignancy. Asymptomatic small lesions are not considered active. Treated lesions may be considered inactive if they are stable for at least 3 months. Patient with malignant cells in their cerebrospinal fluid (CSF) without CNS symptom may be included.
Serious psychiatric or medical conditions that could interfere with treatment
Patients with coagulation problems and active bleeding in the last month (peptic ulcer, epistaxis, spontaneous bleeding)
Patients with signs of gastrointestinal obstruction or uncontrolled vomiting or diarrhea (\>3 episodes/week) with electrolyte abnormalities
Concurrent therapy with approved or investigational anticancer therapeutic agents other than glucocorticoids
Participation in an investigational anti-cancer study within 3 weeks prior to cycle 1 day 1

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Gabrail Cancer Center ResearchCanton, Ohio

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 17, 2019. Always confirm current availability with the study team.

View original record ↗